News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

September 30, 2022 Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
September 12, 2022 Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
September 7, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2022 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 24, 2022 Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
August 8, 2022 Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 4, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 1, 2022 Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
July 27, 2022 Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 19, 2022 Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)